Molbio Diagnostics Q2 FY27 Results: Total Income ₹265 Cr, PAT ₹8 Cr
Molbio Diagnostics reported Q2 FY27 total income of ₹265 crore and PAT of ₹8 crore. H1 FY27 total income was ₹676 crore and PAT was ₹60 crore. The company cited rate-contract negotiations impacting Q2 performance but maintained its FY27 topline growth guidance of 25%. Expansion in R&D and veterinary applications is ongoing.
The decline in revenue and profit for the quarter, though attributed to specific negotiation cycles, could be a concern for investors. However, the company's reiteration of growth guidance and ongoing strategic initiatives in R&D and new markets suggest potential for future recovery and growth.
The results show a year-on-year decline in total income for Q2 FY27, and a decrease in PAT for both Q2 and H1 FY27 compared to the previous year. While the company expresses commitment to future growth and highlights ongoing developments, the financial performance for the quarter was softer than the prior year.
Molbio Diagnostics Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026.
For the second quarter of FY27, the company reported a total income of ₹265 crore, a decrease from ₹581.4 crore in Q2 FY26. EBITDA stood at ₹50 crore with a margin of 18.8%, and Profit After Tax (PAT) was ₹8 crore with a margin of 2.9%.
The company highlighted that the softer business performance in Q2 FY27 was due to ongoing rate-contract negotiations, which typically take 1-1.5 months to complete, resulting in a partial quarter of sales. Molbio Diagnostics reiterated its commitment to its guidance of 25% topline growth in FY27 over FY26. The company is also expanding its global presence and strengthening its R&D portfolio, with new platforms under development. Additionally, its radiology products are being deployed for veterinary use, with six new assays in development for veterinary applications.
For the half-year ended September 30, 2027, total income was ₹676 crore, compared to ₹681.8 crore in the same period last year. EBITDA was ₹153 crore with a margin of 22.7%, and PAT was ₹60 crore with a margin of 8.9%.
The investor presentation also detailed the company's business overview, financial performance for FY26, revenue mix, R&D initiatives, manufacturing capabilities, and growth strategy, emphasizing its proprietary Truenat platform and its recurring revenue model driven by test kit consumption.
What to do with a filing like this
Molbio Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Molbio Diagnostics Limited. Read the original for the full detail.